{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Anemia&page=8", "query": { "condition": "Anemia", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 2062, "total_pages": 207, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Anemia&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Anemia&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T03:07:53.156Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06303193", "title": "Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myelodysplastic Syndromes" ], "interventions": [ { "name": "pacritinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "12 Years to 120 Years" }, "enrollment_count": 160, "start_date": "2026-10-22", "completion_date": "2035-01-01", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-20T03:07:53.156Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06303193" }, { "nct_id": "NCT04439006", "title": "Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Aplastic Anemia", "Hematopoietic and Lymphoid Cell Neoplasm", "Malignant Solid Neoplasm", "Monoclonal B-Cell Lymphocytosis", "Monoclonal Gammopathy of Undetermined Significance", "Myelodysplastic Syndrome", "Symptomatic COVID-19 Infection Laboratory-Confirmed" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Ibrutinib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Jennifer Woyach", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2020-10-23", "completion_date": "2022-09-20", "has_results": false, "last_update_posted_date": "2023-12-26", "last_synced_at": "2026-10-20T03:07:53.156Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04439006" }, { "nct_id": "NCT01773187", "title": "Pacritinib Versus Best Available Therapy to Treat Myelofibrosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Primary Myelofibrosis", "Post-polycythemia Vera Myelofibrosis", "Post-essential Thrombocythemia Myelofibrosis" ], "interventions": [ { "name": "Pacritinib", "type": "DRUG" }, { "name": "Best Available Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CTI BioPharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 327, "start_date": "2013-01", "completion_date": "2016-04", "has_results": true, "last_update_posted_date": "2020-09-29", "last_synced_at": "2026-10-20T03:07:53.156Z", "location_count": 4, "location_summary": "Scottsdale, Arizona • Omaha, Nebraska • Morristown, New Jersey + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Morristown", "state": "New Jersey" }, { "city": "Greenville", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01773187" }, { "nct_id": "NCT00210626", "title": "Assess Functional Outcomes in Anemic, Critically Ill, Trauma Patients When Taking Epoetin Alfa", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anemia" ], "interventions": [ { "name": "PROCRIT", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 192, "start_date": "2005-08", "completion_date": "2008-06", "has_results": true, "last_update_posted_date": "2014-04-21", "last_synced_at": "2026-10-20T03:07:53.156Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Orange, California • Santa Barbara, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00210626" }, { "nct_id": "NCT00015925", "title": "MS-275 in Treating Patients With Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "entinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2001-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2010-03-10", "last_synced_at": "2026-10-20T03:07:53.156Z", "location_count": 2, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00015925" }, { "nct_id": "NCT01297543", "title": "Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Lymphoblastic Leukemia", "Chronic Myeloid Leukemia", "Myelodysplasia" ], "interventions": [ { "name": "human myeloid progenitor cells", "type": "BIOLOGICAL" }, { "name": "G-CSF", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Cellerant Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2011-03", "completion_date": "2015-01", "has_results": false, "last_update_posted_date": "2016-07-01", "last_synced_at": "2026-10-20T03:07:53.156Z", "location_count": 10, "location_summary": "La Jolla, California • San Francisco, California • Stanford, California + 7 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Beech Grove", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01297543" }, { "nct_id": "NCT02098863", "title": "Sickle Cell Clinical Research and Intervention Program", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Sickle Cell Disease" ], "interventions": [], "intervention_types": [], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 10000, "start_date": "2014-04-15", "completion_date": "2044-12", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-10-20T03:07:53.156Z", "location_count": 6, "location_summary": "Peoria, Illinois • Baton Rouge, Louisiana • Charlotte, North Carolina + 1 more", "locations": [ { "city": "Peoria", "state": "Illinois" }, { "city": "Baton Rouge", "state": "Louisiana" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02098863" }, { "nct_id": "NCT01135849", "title": "B-Receptor Signaling in Cardiomyopathy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Carcinomas", "Amyloidosis", "Anal Cancer", "Anemia", "Cholangiocarcinoma of the Extrahepatic Bile Duct", "Transitional Cell Carcinoma of Bladder", "Bone Marrow Transplant Failure", "Bone Cancer", "Cancer of Brain and Nervous System", "Breast Cancer", "Carcinoma of the Large Intestine", "Endocrine Cancer", "Esophageal Cancer", "Eye Cancer", "Gall Bladder Cancer", "Gastric (Stomach) Cancer", "Gastrooesophageal Cancer", "Gastrointestinal Stromal Tumor (GIST)", "Gynecologic Cancers", "Head and Neck Cancers", "Hepatobiliary Neoplasm", "Kidney (Renal Cell) Cancer", "Leukemia", "Lung Cancer", "Hodgkin Disease", "Lymphoma, Non-Hodgkin", "Mesothelioma", "Multiple Myeloma", "Myelodysplastic Syndromes (MDS)", "Neuroendocrine Tumors", "Myeloproliferative Disorders", "Pancreatic Cancer", "Prostate Cancer", "Skin Cancer", "Soft Tissue Sarcoma", "Testicular Cancer", "Thymus Cancer", "Thyroid Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Daniel Bernstein", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "40 Years", "sex": "ALL", "summary": "Up to 40 Years" }, "enrollment_count": 99, "start_date": "2008-11", "completion_date": "2010-10", "has_results": false, "last_update_posted_date": "2015-11-17", "last_synced_at": "2026-10-20T03:07:53.156Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01135849" }, { "nct_id": "NCT00001958", "title": "Hydroxyurea to Treat Beta-Thalassemia (Cooley's Anemia)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Beta Thalassemia", "Hemoglobinopathy" ], "interventions": [ { "name": "Hydroxyurea", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 100, "start_date": "1999-12", "completion_date": "2002-02", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-10-20T03:07:53.156Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001958" }, { "nct_id": "NCT01959958", "title": "Evaluation of Nocturnal Enuresis and Barriers to Treatment Among Pediatric Patients With Sickle Cell Disease", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Questionnaire/Interview", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Years to 17 Years" }, "enrollment_count": 250, "start_date": "2013-10", "completion_date": "2016-04", "has_results": false, "last_update_posted_date": "2016-05-11", "last_synced_at": "2026-10-20T03:07:53.156Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01959958" } ] }